File Semorelin For Growth Hormone Deficiency[1]

Sermorelin for Growth Hormone Deficiency: Major advances in medicine are often met with fervent opposition because the approaching paradigm shift has economic, political and social ramifications that are a threat to the status quo. The birth of anti-aging medicine has been no different as sensationalistic tabloid style propaganda serves to drown out the voice of scientific, evidence based medicine. Human Growth Hormone (HGH) has risen as the primary scapegoat in antiaging medicine…it is now illegal to prescribe HGH for anti-aging purposes! There really isn’t much compelling evidence that mainstream anti-aging medicine can extend lifespan appreciably. However, there is plenty of evidence that it can extend “healthspan” so that a patient can enjoy lifelong health. In other words, the last 20-40 years of life can be vibrant and active instead of a continuous downhill slide full of pain, misery, and diminishing function. Maximum Life is not about living longer; it is about living better longer. Utilization of HGH has been a cornerstone of the anti-aging movement, but law-abiding physicians can no longer view this wonderful naturally occurring substance as a weapon to be prescribed in the fight against aging. Congress and the FDA have increased the stakes…now our challenge is to find ways to encourage your own body to increase production of growth hormone. Proper nutrition, exercise, and REM sleep all have been proven to increase growth hormone production. Unfortunately, the aging pituitary gland (site of HGH production) becomes less responsive to these stimuli and thus growth hormone levels fall. This leads to a cascade of negative events that can best be described as aging. Fortunately, the pituitary gland can respond to a chemical “signal” from the brain that tells it to produce more growth hormone. Unfortunately, this part of the brain also falls victim to the aging process and therefore as we get older the intensity of this “signal” fades. Now for the really good news…we can mimic the brain “signal” utilizing Sermorelin (a growth hormone releasing factor). Sermorelin is an identical replicate of the active portion (the first 29 amino acids) of Growth Hormone Releasing Hormone (GHRH) that is normally produced in the hypothalamus (brain). GHRH serves to “signal” the pituitary gland to produce and release more growth hormone. Sermorelin can provide this signal in identical fashion (Walker, 2006). Sermorelin has an excellent safety profile, ultimately produces the same end

organ effects as HGH (because its’ only mechanism of action is through HGH production), preserves feedback mechanisms that regulate the pituitary gland (making overdose less likely), and can be used legally in anti-aging medicine (Merriam et al., 2001). By the age of 50, most of us are functioning with 50% of the HGH levels we enjoyed in our twenties with even greater declines ahead. In a HGH deficient patient, the correction of low HGH levels can have a profound and far-reaching impact on all areas of life including: --Body composition (reduced body fat / increased lean muscle mass) --Lipid profiles --Cardiovascular capacity, endurance, energy, peak exercise capability --Improved mood / memory / cognitive function --Improved sleep / bone density / immune function / sexual function ….and the list goes on and on. If your HGH levels are symptomatically low, the best practice of medicine is going to find a way to normalize them legally and responsibly. Sermorelin is a powerful tool in this quest. The “Great Hormone Debate” continues (Landsmann, 2006).

References

Landsmann, M.A. (2006). Forever Young? What role does HGH play in the aging process? The question is rife with controversy. ADVANCE for Healthy Aging 2, 54-61. Merriam, G.R., Barness, S., Buchner, D. (2001). Growth hormone releasing hormone treatment in normal aging. Journal of Anti-Aging Medicine 4, 331-343. Walker, R.F. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4)1-2.